Management of recurrent cutaneous abscesses during therapy with infliximab

Clara De Simone, Rita Murri, Alessia Maiorino, Antonio Venier, Giacomo Caldarola

Risultato della ricerca: Contributo in rivistaArticolo in rivista

5 Citazioni (Scopus)


Infliximab is a chimeric monoclonal antibody, belonging to the class of anti-tumor necrosis factor-α (TNF-α) agents, approved for the treatment of psoriasis and psoriatic arthritis. Drugs of this class are known to be associated with an infective risk, probably because they interfere with inflammatory and immune response at different levels. Although cutaneous Staphylococcus aureus infections seem to be more frequent than any other infection in the course of anti-TNF-α treatment, only a few case reports in the literature deal with this side effect, and, in particular, with its management.
Lingua originaleEnglish
pagine (da-a)1993-1996
Numero di pagine4
RivistaClinical Therapeutics
Stato di pubblicazionePubblicato - 2011


  • Abscess
  • Administration, Oral
  • Amoxicillin-Potassium Clavulanate Combination
  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents
  • Antibiotic Prophylaxis
  • Antibodies, Monoclonal
  • Arthritis, Psoriatic
  • Drug Administration Schedule
  • Female
  • Humans
  • Infusions, Intravenous
  • Microbial Sensitivity Tests
  • Middle Aged
  • Recurrence
  • Staphylococcal Skin Infections
  • Staphylococcus aureus
  • Treatment Outcome


Entra nei temi di ricerca di 'Management of recurrent cutaneous abscesses during therapy with infliximab'. Insieme formano una fingerprint unica.

Cita questo